Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rivaroxaban Versus Acenocumarol for Secondary Thromboprophylaxis in Patients With Antiphospholipid Syndrome: a Randomized, Prospective, Phase III Study. Analysis of Stratification Prognostic Factors

Trial Profile

Rivaroxaban Versus Acenocumarol for Secondary Thromboprophylaxis in Patients With Antiphospholipid Syndrome: a Randomized, Prospective, Phase III Study. Analysis of Stratification Prognostic Factors

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Oct 2018

At a glance

  • Drugs Rivaroxaban (Primary) ; Acenocoumarol
  • Indications Antiphospholipid syndrome; Thrombosis
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 24 Oct 2018 Primary endpoint has not been met. (Incidence of major bleeding)
    • 24 Oct 2018 Primary endpoint has not been met. (Developement of a new thrombotic event (arterial or venous), confirmed by appropiate imaging studies)
    • 24 Oct 2018 Results of per-protocol analysis designed to determine the rivaroxaban noninferiority to warfarin, presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top